David Braga Malta is a Life Sciences Entrepreneur, Inventor and Investor. David founded LiMM, Cell2B and BoostPharma, where he serves(ed) as manager. Cell2B focused on the development of cell therapies for the cure of immune and inflammatory diseases. The leading program of the company, for acute Graft versus Host Disease reach first in man with promising results. From there David is acted as Venture Consultant for Caixa Capital, helping to establish a Life Sciences investment policy for Portugal.
Now, David is Venture Partner at Vesalius Biocapital.
David holds a PhD in Bioengineering from the MIT Portugal Program and a M.Sc. Degree in Biological Engineering, Instituto Superior Técnico, Portugal (class valedictorian). During his master David attended the Imperial College of London as a visiting scientist working on stem cell based regeneration of lung tissue, his work focused on the derivation of type 2 pneumocytes from stem cells.
For his PhD, David worked at MIT on stem cell based therapies at the Koch Institute. David developed high-throughput platforms for the study of cell and extracellular matrix interactions. His academic career focuses on the field of regenerative medicine with different publications and patents in the field.
One of his greatest passions as always been entrepreneurship. David has participated and been awarded in different competitions as a graduate student and translated this passion into the companies he founded.
In parallel and committed to improving the state of the world, David was nominated a World Economic Forum Global Shaper having served as the curator of the Lisbon Hub.
Currently, David is involved in the inception of new bio-ventures actively scouting for disruptive technologies to build transformative companies around.